Data showed NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumor binding Another set of data detailed the design of LIGHT, an immunomodulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results